ACADIA Pharmaceuticals Stock Forecast, Price & News

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given ACADIA Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ACADIA Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ACADIA Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 8,170,000 shares, an increase of 36.9% from the June 15th total of 5,970,000 shares. Based on an average trading volume of 1,860,000 shares, the days-to-cover ratio is currently 4.4 days. Approximately 5.1% of the company's stock are sold short.
View ACADIA Pharmaceuticals' Short Interest.

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "8065926".

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.11. The biopharmaceutical company had revenue of $106.55 million for the quarter, compared to the consensus estimate of $112.91 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 41.17% and a negative net margin of 56.74%.
View ACADIA Pharmaceuticals' earnings history.

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACAD stock has decreased by 39.9% and is now trading at $22.15.
View which stocks have been most impacted by COVID-19.

ACADIA Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $510 million-$550 million, compared to the consensus revenue estimate of $535.93 million.

18 analysts have issued twelve-month price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $18.00 to $57.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $30.42 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts.

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Some companies that are related to ACADIA Pharmaceuticals include Zai Lab (ZLAB), Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), CureVac (CVAC), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), HUTCHMED (HCM) and Arrowhead Pharmaceuticals (ARWR).
View all of ACAD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

ACADIA Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hohimer Wealth Management LLC (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

ACAD stock was bought by a variety of institutional investors in the last quarter, including Hohimer Wealth Management LLC.
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACAD stock can currently be purchased for approximately $22.15.

ACADIA Pharmaceuticals has a market capitalization of $3.55 billion and generates $441.76 million in revenue each year. The biopharmaceutical company earns $-281,580,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

ACADIA Pharmaceuticals employs 601 workers across the globe.

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871 or via email at [email protected]